Treatment of patients with advanced cardiac AL amyloidosis with oral melphalan, dexamethasone, and thalidomide

被引：0
作者：
Giovanni Palladini
Paola Russo
Francesca Lavatelli
Mario Nuvolone
Riccardo Albertini
Tiziana Bosoni
Vittorio Perfetti
Laura Obici
Stefano Perlini
Remigio Moratti
Giampaolo Merlini
机构：
[1] “Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Matteo” and University of Pavia,Biotechnology Research Laboratories, Center for Amyloidosis, Department of Biochemistry
[2] “Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS.) San Matteo” and University of Pavia,Department of Internal Medicine
[3] “Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Matteo” and University of Pavia,Clinical Chemistry Laboratory
来源：
Annals of Hematology | 2009年 / 88卷
关键词：
Amyloidosis; Melphalan; Dexamethasone; Thalidomide; Response;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Patients with primary (AL) amyloidosis and heart failure have a very poor prognosis and cannot tolerate aggressive therapy, such as autologous stem cell transplantation and high-dose dexamethasone-based regimens. We prospectively treated 22 patients with advanced cardiac amyloidosis combining oral melphalan, thalidomide, and reduced intensity dexamethasone (MTD). Six patients died due to cardiac amyloidosis before completing cycle 3. Early death was associated with reduced ejection fraction. Eight patients achieved a hematological response and four achieved a durable improvement of cardiac dysfunction. Treatment with MTD is feasible in patients with advanced cardiac AL amyloidosis and effective in subjects with preserved systolic function.
引用
收藏
页码：347 / 350
页数：3
相关论文
共 35 条
  • [1] Merlini G(2006)Dangerous small B-cell clones Blood 108 2520-2530
  • [2] Stone MJ(2004)Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation Blood 103 2936-2938
  • [3] Palladini G(2007)High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis N Engl J Med 357 1083-1093
  • [4] Perfetti V(2007)Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis Blood 109 457-464
  • [5] Obici L(2001)A modified high-dose dexamethasone regimen for primary systemic (AL) amyloidosis Br J Haematol 113 1044-1046
  • [6] Jaccard A(2006)Sequential heart and autologous stem cell transplantation for systemic AL amyloidosis Blood 107 1227-1229
  • [7] Moreau P(2004)Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis J Clin Oncol 22 3751-3757
  • [8] Leblond V(2006)Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial Lancet 367 825-831
  • [9] Wechalekar AD(2007)Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial Lancet 370 1209-1218
  • [10] Goodman HJ(2005)Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18–22 April 2004 Am J Hematol 79 319-328
1234